Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription 04.08.2025 1 ACS Nano 1 Asian Pac J Cancer Prev 1 Biomedicines 1 BJU Int 1 BJUI Compass 9 Bladder (San Franc) 1 Cancer Immunol Immunother 1 Cancer Med 1 Cancer Radiother 1 Case Rep Urol 1 Clin Genitourin Cancer 2 Clin Nucl Med 1 Crit Rev Oncol Hematol 1 Cureus 1 Curr Med Chem 1 Diagnostics (Basel) 1 Discov Oncol 1 Eur Urol 1 Fr J Urol 1 Front Immunol 1 Front Oncol 1 Int J Urol 1 Iran J Pathol 1 J Anesth 1 J Cancer 2 J Clin Med 1 J Clin Oncol 1 J Transl Med 1 J Vasc Surg Cases Innov Tech 1 J Vis Exp 1 JAAPA 1 Med Lett Drugs Ther 2 Medicina (Kaunas) 1 Mol Carcinog 1 Oncogene 1 Res Rep Urol 2 Scand J Urol 1 Sci Prog 1 Sci Rep 1 Ther Adv Med Oncol 1 Urology 1 World J Clin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Nano

1. TANG T, Kong S, Xie J, Deng Q, et al
   Prolonged Release of Bacillus Calmette-Guerin by Floating Microbubbles to Enhance Intravesical Immunotherapy for Bladder Cancer.
   ACS Nano. 2025 Jul 28. doi: 10.1021/acsnano.5c06540.
   PubMed         Abstract available
   
   

   
   Asian Pac J Cancer Prev

2. HAMMAD G, Magdy M, Aboushousha T, Safwat G, et al
   Decreased Expression Levels Of PIWIL2, PIWIL3 and PIWIL4 Are Associated with Poor Prognosis and Worse Survival in Bladder Cancer Patients.
   Asian Pac J Cancer Prev. 2025;26:2467-2477.
   PubMed         Abstract available
   
   

   
   Biomedicines

3. AHMED MY, Cakir MO, Sandhu S, Ashrafi GH, et al
   Detection of High-Risk Human Papillomavirus in Bladder Cancer: An Exploratory Study from a UK-Based Population.
   Biomedicines. 2025;13:1548.
   PubMed         Abstract available
   
   

   
   BJU Int

4. LONGONI M, Scilipoti P, Zaurito P, Moschini M, et al
   Response to Hof et al.: spurious associations between BCG instillations and outcomes in non-muscle-invasive bladder cancer.
   BJU Int. 2025 Jul 29. doi: 10.1111/bju.16867.
   PubMed        
   
   

   
   BJUI Compass

5. MARTIN R, Wylie H, Moss C, Hafeez S, et al
   Understanding oncological and sexual function outcomes with gynaecological organ preserving cystectomy in women with bladder cancer; a systematic review.
   BJUI Compass. 2025;6:e70053.
   PubMed         Abstract available
   
   

   
   Bladder (San Franc)

6. PATEL M, Rajagopalan A, Cahill EM, Chua KJ, et al
   Tolerability and efficacy of induction Bacillus Calmette-Guerin for non-muscle invasive bladder cancer.
   Bladder (San Franc). 2025;12:e21200031.
   PubMed         Abstract available
   
   
7. ZHU H, Li J, Zhou X, Mi K, et al
   Advances in recombinant Bacillus Calmette-Guerin therapy for bladder cancer from 2015 to 2024: Innovations and challenges.
   Bladder (San Franc). 2025;12:e21200047.
   PubMed         Abstract available
   
   
8. HEGAZI MAAA, Pasqualini F, Chiriva-Internati M, Taverna G, et al
   SPEF1 and SPEF2 as potential biomarkers in bladder cancer: Insights from a comprehensive bioinformatic analysis.
   Bladder (San Franc). 2025;12:e21200039.
   PubMed         Abstract available
   
   
9. JAFRI A, Hubbard R, Hussain SA
   Potential synergistic effect of radiotherapy and immune checkpoint inhibitors on advanced bladder cancer: A case report.
   Bladder (San Franc). 2025;12:e21200045.
   PubMed         Abstract available
   
   
10. KORKES F, Santiago JHD, Pinto AMM, Farias ADS, et al
    Kidney function improvement after urinary diversion for cisplatin eligibility in bladder cancer patients.
    Bladder (San Franc). 2025;12:e21200027.
    PubMed         Abstract available
    
    
11. HYLDGAARD J, Als AB, Ulhoi B, Jensen J, et al
    Assessment of lower urinary tract symptoms and their impact on quality of life following radiation therapy for bladder cancer.
    Bladder (San Franc). 2025;12:e21200033.
    PubMed         Abstract available
    
    
12. WU Y, Zhang F, Ying Y, Li J, et al
    The role and clinical potential of RNA modifications in bladder cancer.
    Bladder (San Franc). 2025;12:e21200037.
    PubMed         Abstract available
    
    
13. ROESCH HRM, Jalalizadeh M, de Oliveira C, Reis LO, et al
    Trends in surgical procedures for bladder cancer within the Brazilian public health system: An 11-year analysis.
    Bladder (San Franc). 2025;12:e21200030.
    PubMed         Abstract available
    
    
14. LIU C, Lu J, Lai J, Jie K, et al
    Advancements in genetic circuits as part of intelligent biotherapy for the treatment of bladder cancer: A review.
    Bladder (San Franc). 2025;12:e21200032.
    PubMed         Abstract available
    
    

    
    Cancer Immunol Immunother

15. MAHMOUD H, Abd El-Aziz AM, Ezzat O, Kenawy HI, et al
    Prediction of response to neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder cancer: role of immune-related gene expression.
    Cancer Immunol Immunother. 2025;74:279.
    PubMed         Abstract available
    
    

    
    Cancer Med

16. LI Z, Xia L, Li Y, Huang T, et al
    Diagnostic Values of Electrochemiluminescent Detection of Urinary CYFRA21-1 and FDP and Their Combined Detection in Bladder Cancer.
    Cancer Med. 2025;14:e71056.
    PubMed         Abstract available
    
    

    
    Cancer Radiother

17. BLACHE A, Huck C, Achard V, Coutte A, et al
    Hypofractionated radiotherapy in the management of bladder cancer.
    Cancer Radiother. 2025;29.
    PubMed         Abstract available
    
    

    
    Case Rep Urol

18. FENTON D, Han S, Lee A, Perez AH, et al
    A Case of Malignant Priapism Secondary to Muscle Invasive Bladder Cancer and Review of Palliative Management.
    Case Rep Urol. 2025;2025:2340917.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

19. SHORE ND, Chevli KK, Saltzstein D, Ehrlich Y, et al
    Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.
    Clin Genitourin Cancer. 2025 Jun 25:102392. doi: 10.1016/j.clgc.2025.102392.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

20. ZHANG L, Tian J, Huang H
    Primary Extranodal Natural Killer/T-cell Lymphoma of the Bladder on 18F-FDG PET/CT.
    Clin Nucl Med. 2025 May 13. doi: 10.1097/RLU.0000000000005956.
    PubMed         Abstract available
    
    
21. GHORBANI H, Saber Tanha A, Ataei N, Ataei R, et al
    Metastasis of Urothelial Carcinoma to the Wrist: A Case Report of an Overlooked Finding on Whole-body 99m Tc-MDP Scan.
    Clin Nucl Med. 2025;50:e561-e563.
    PubMed         Abstract available
    
    

    
    Crit Rev Oncol Hematol

22. FERRO M, Crocetto F, Jannello LMI, Contieri R, et al
    Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology.
    Crit Rev Oncol Hematol. 2025;215:104862.
    PubMed         Abstract available
    
    

    
    Cureus

23. RANJITH S, Thomas Jacob A, Augustine P, K C, et al
    Survival Outcomes in Bladder Cancer: An Ambispective Study of Patients Undergoing Radical Cystectomy.
    Cureus. 2025;17:e86938.
    PubMed         Abstract available
    
    

    
    Curr Med Chem

24. WAN X, Wang K, Ren P, Zhang X, et al
    Circadian Rhythm Genes-based Prognostic Signature for Bladder Cancer: Association of EZH2 Expression with Anesthetic-related Changes in Circulating Tumor Cells.
    Curr Med Chem. 2025 Jul 28. doi: 10.2174/0109298673362736250702043230.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

25. TANAKA S, Shimizu T, Pagano I, Hogrefe W, et al
    Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay Using Three Different Luminex xMAP Instruments.
    Diagnostics (Basel). 2025;15:1749.
    PubMed         Abstract available
    
    

    
    Discov Oncol

26. PENG J, Li D, Xiang B, Li Z, et al
    Knockdown of CSF1R molecules enhances the antitumor effects of CD8(+) T lymphocytes in bladder cancer.
    Discov Oncol. 2025;16:1426.
    PubMed         Abstract available
    
    

    
    Eur Urol

27. GUO Y, Zhang W, Zhang J, Mao S, et al
    Re: Oncolytic Immunotherapy with Nivolumab in Muscle-invasive Bladder Cancer: A Phase 1b Trial.
    Eur Urol. 2025 Jul 28:S0302-2838(25)00406-3. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    

    
    Fr J Urol

28. SZOSTEK A, Khadhouri S, Gallagher KM, MacKenzie KR, et al
    Bladder cancer prevalence and diagnostic test accuracy: French results from the IDENTIFY study.
    Fr J Urol. 2025 Jul 24:102935. doi: 10.1016/j.fjurol.2025.102935.
    PubMed         Abstract available
    
    

    
    Front Immunol

29. ZHAO Y, Xing Z, Zhao Y, Xu H, et al
    Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer.
    Front Immunol. 2025;16:1585727.
    PubMed         Abstract available
    
    

    
    Front Oncol

30. ATTANASIO G, Failla M, Poidomani S, Buzzanca T, et al
    Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer.
    Front Oncol. 2025;15:1546160.
    PubMed         Abstract available
    
    

    
    Int J Urol

31. GOTO Y
    Editorial Comment on "Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer".
    Int J Urol. 2025 Jul 27. doi: 10.1111/iju.70184.
    PubMed        
    
    

    
    Iran J Pathol

32. NIKOOBAKHT MR, Esmaeilpanah S, Menbari Oskouie I, Khoshchehreh M, et al
    Association of Thrombomodulin Expression with Bladder Cancer Grade, Stage, and Recurrence: A Single-Center Prospective Pilot Study.
    Iran J Pathol. 2025;20:266-272.
    PubMed         Abstract available
    
    

    
    J Anesth

33. YOSHIDA T, Nakano Y, Kitada M, Nakamoto T, et al
    Ultrasound-guided obturator nerve block technique at the distal end of the obturator canal: case series and cadaver evaluation.
    J Anesth. 2025;39:652-656.
    PubMed         Abstract available
    
    

    
    J Cancer

34. ZUO J, Chen J, Tan Z, Wen L, et al
    Comprehensive Mendelian randomization and colocalization analysis of plasma proteomics to identify new therapeutic targets for bladder cancer.
    J Cancer. 2025;16:3163-3179.
    PubMed         Abstract available
    
    

    
    J Clin Med

35. DULF DV, Burnar AL, Dulf PL, Matei DR, et al
    Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy.
    J Clin Med. 2025;14:5120.
    PubMed         Abstract available
    
    
36. PORRECA A, Marino F, De Marchi D, Crestani A, et al
    Robot-Assisted Radical Cystectomy with Ureterocutaneostomy: A Potentially Optimal Solution for Octogenarian and Frail Patients with Bladder Cancer.
    J Clin Med. 2025;14:4898.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

37. DANESHMAND S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, et al
    TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
    J Clin Oncol. 2025 Jul 30:101200JCO2501651. doi: 10.1200/JCO-25-01651.
    PubMed         Abstract available
    
    

    
    J Transl Med

38. ZHAO X, Wang X, Wu G
    Letter to editor: SRSF1-mediated alternative splicing regulates bladder cancer progression and cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis.
    J Transl Med. 2025;23:839.
    PubMed        
    
    

    
    J Vasc Surg Cases Innov Tech

39. PASSOS L, Dabravolskaite V, Kotelis D, Makaloski V, et al
    Successful complex endovascular treatment of a contained rupture of a thoracoabdominal aortic aneurysm caused by Mycobacterium bovis after intravesical Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    J Vasc Surg Cases Innov Tech. 2025;11:101895.
    PubMed         Abstract available
    
    

    
    J Vis Exp

40. ZHANG DY, Sali R, Zhu M, Zhang V, et al
    Introduction of an Integrated Pathology Image Management, Artificial Intelligence, and Reporting System.
    J Vis Exp. 2025;.
    PubMed         Abstract available
    
    

    
    JAAPA

41. SOLANO L
    Bladder cancer.
    JAAPA. 2025;38:45-46.
    PubMed        
    
    

    
    Med Lett Drugs Ther

42. 
    Intravesical mitomycin (Zusduri) for bladder cancer.
    Med Lett Drugs Ther. 2025;67:e128-e129.
    PubMed        
    
    

    
    Medicina (Kaunas)

43. VRABIE CR, Parosanu AI, Nitipir C
    Sarcopenia in Urothelial Bladder Carcinoma: A Narrative Review.
    Medicina (Kaunas). 2025;61:1307.
    PubMed         Abstract available
    
    
44. CHO SY, Jung KT
    Adductor Muscle Contraction Under Deep Neuromuscular Blockade During TURBT Under General Anesthesia: Is Obturator Nerve Block Still Necessary?-A Prospective, Single-Arm, Exploratory Study.
    Medicina (Kaunas). 2025;61:1207.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

45. CHEN J, Hu M, Wang P, Lin R, et al
    MYEOV Facilitates the Progression of Bladder Cancer by Upregulating MMP9 Via the TGF-beta-H3K4me3 Epigenetic Axis.
    Mol Carcinog. 2025 Jul 31. doi: 10.1002/mc.70001.
    PubMed         Abstract available
    
    

    
    Oncogene

46. HU H, Zhan X, Xiong Y, Yuan R, et al
    Retraction Note: Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A.
    Oncogene. 2025 Jul 30. doi: 10.1038/s41388-025-03520.
    PubMed        
    
    

    
    Res Rep Urol

47. SUN L, Liu C, Cao Y, Li J, et al
    As a New Tumor Suppressor Gene, PID1 Activates the AMPK-mTOR Signal to Inhibit the Progression of Bladder Cancer.
    Res Rep Urol. 2025;17:235-248.
    PubMed         Abstract available
    
    

    
    Scand J Urol

48. TORIKKA SUUA S, Porserud A, Nygren-Bonnier M, Hagstromer M, et al
    Association between physical function before radical cystectomy for urinary bladder cancer and recovery after discharge from hospital.
    Scand J Urol. 2025;60:135-140.
    PubMed         Abstract available
    
    
49. MILLING RV, Nielsen NK, Graugaard-Jensen C, Christensen P, et al
    Long-term effect of treatment for non-muscle invasive bladder cancer on Quality of life: a cross-sectional study.
    Scand J Urol. 2025;60:141-147.
    PubMed         Abstract available
    
    

    
    Sci Prog

50. SHEN C, Ni H, Chen Z, You J, et al
    Predictive model of double-J pipe scab size after radical total cystectomy based on Boruta feature selection and LASSO technique: A retrospective cross-sectional study.
    Sci Prog. 2025;108:368504251363901.
    PubMed         Abstract available
    
    

    
    Sci Rep

51. QIN H, Hashem AF, Hanif MF, Fiidow OA, et al
    Graph theoretic and machine learning approaches in molecular property prediction of bladder cancer therapeutics.
    Sci Rep. 2025;15:28025.
    PubMed         Abstract available
    
    

    
    Ther Adv Med Oncol

52. CHEN J, Yang X, Hao Z, Guo H, et al
    Extracellular vesicles-derived extracellular RNA in bladder cancer: current progress and future prospects.
    Ther Adv Med Oncol. 2025;17:17588359251349288.
    PubMed         Abstract available
    
    

    
    Urology

53. OBIORA D, Yu M, Sharbaugh D, Bandari J, et al
    Treatment Patterns for Non-Muscle Invasive Bladder Cancer during the Bacillus Calmette-Guerin shortage.
    Urology. 2025 Jul 23:S0090-4295(25)00711-3. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available
    
    

    
    World J Clin Oncol

54. SHI MM, Guan MY, Li S, Guo JY, et al
    HOXC6-TIMELESS axis: Unveiling novel therapeutic strategies in bladder cancer.
    World J Clin Oncol. 2025;16:108071.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.